Intrinsically disordered proteins defy classical paradigms, lacking a stable three-dimensional structure and instead existing as dynamic, fluctuating regions within cells. Their shapeshifting nature has made them elusive to traditional small-molecule drugs, which typically latch onto well-defined, stable binding sites. These proteins play pivotal roles in a broad spectrum of pathologies, including various cancers, neurodegenerative disorders, cardiovascular ailments, and autoimmune diseases, yet pharmaceutical interventions targeting them have remained limited and largely ineffective.

The new study, recently published in the journal Signal Transduction and Targeted Therapy, presents a pioneering approach that contravenes the lock-and-key model of drug design. By designing compounds capable of binding with extraordinary affinity—up to a million-fold stronger than previously reported—the research team successfully inhibited the pathological activity of IDPs. This marks a paradigm shift, transforming a perceived boundary in molecular pharmacology into fertile ground for therapeutic innovation.

Central to their investigation is the androgen receptor (AR), a disordered protein whose aberrant activity drives the progression of the majority of prostate cancers. Unlike conventional drugs that target stable receptor domains, the researchers crafted molecules that interact with the receptor’s intrinsically disordered transactivation domain. By effectively “freezing” this mobile region in an inactive conformation, these compounds prevent the AR from activating gene expression programs that fuel cancer proliferation.

This strategy required overcoming formidable scientific challenges. Disordered proteins’ lack of fixed binding sites renders classical rational drug design ineffective. Dr. Marianne D. Sadar, the principal investigator, emphasizes the complexity of this endeavor by likening IDPs to “moving strands of spaghetti” rather than static locks. The team’s extensive expertise, cultivated over decades, laid the groundwork for this success, having previously developed the first compound targeting IDPs in 2008 and progressed others into clinical trials, a world-first milestone.

Through iterative molecular modifications and rigorous biochemical assays, several candidate compounds emerged, demonstrating potent antagonism of the androgen receptor in vitro. Subsequent in vivo assessments in animal models revealed that these novel molecules suppressed prostate tumor growth more effectively than established therapies. This enhanced efficacy was especially notable in models resistant to current treatment options, underscoring the potential to address drug resistance—a major hurdle in oncology.

The implications extend beyond prostate cancer. Intrinsically disordered proteins are integral to numerous signaling pathways implicated in diverse diseases. By establishing a methodological framework to pharmacologically modulate these elusive targets, this discovery could unlock therapeutic avenues across oncology, neurology, cardiology, and immunology. The approach redefines what constitutes a druggable target, expanding the molecular landscape accessible to medicinal chemists.

Dr. Natalie Strynadka, a co-author and professor of biochemistry, highlights the remarkable binding affinity achieved, describing it as a “major achievement” that challenges and expands conventional wisdom in protein-ligand interactions. Complementing this, Dr. Raymond Andersen, a chemistry expert, remarked on the surprising efficacy of these molecules in stabilizing highly dynamic protein regions, achieving functional inhibition where previous drugs faltered.

Looking forward, the research team aims to transition their most promising candidates into clinical evaluation, with the goal of providing prostate cancer patients with treatments that not only improve efficacy but also reduce side effects. Early intervention with these drugs could transform patient outcomes by effectively neutralizing AR-driven oncogenic signals before the emergence of resistance.

Beyond clinical translation, this innovation has profound consequences for the broader drug discovery community. By demonstrating that highly flexible, disordered protein domains can be locked into therapeutic conformations, it challenges the dogma that only well-structured proteins are viable drug targets. This could catalyze a wave of research endeavors focusing on previously neglected protein classes, accelerating the development of drugs for a variety of hitherto refractory conditions.

This research was supported by the U.S. National Institutes of Health (NIH)/National Cancer Institute (NCI) as well as donations from Country Meadows Senior Men’s Golf Charity and the BC Cancer Foundation, underscoring the collaborative nature of cutting-edge biomedical research. The team’s multidisciplinary expertise in biochemistry, molecular biology, and chemistry was crucial for the success of this interdisciplinary project.

In summation, this achievement opens an inspiring new frontier in precision medicine. By drugging the “undruggable,” the researchers have not only forged new weapons against prostate cancer but also illuminated a path forward for numerous other diseases driven by intrinsically disordered proteins. The promise of converting molecular complexity into druggable vulnerability may soon translate into tangible clinical benefits, reshaping therapeutic landscapes across the biomedical field.

Subject of Research: Cells

Article Title: Drugging the intrinsically disordered transactivation domain of androgen receptor

News Publication Date: 27-Apr-2026

Web References:

• Nature Signal Transduction and Targeted Therapy – DOI:10.1038/s41392-026-02642-3

Keywords: Drug discovery, Cancer, Prostate cancer, Proteins, Signal transduction, Protein interactions, Drug resistance, Pharmacology, Molecular biology

Intrinsically disordered proteins evade conventional drug design strategies because they do not adopt a permanent three-dimensional conformation. Instead, they exist as dynamic ensembles of flexible structures, rendering traditional lock-and-key binding models ineffective. The research, led by Dr. Xavier Salvatella, overturns this dogma by demonstrating that during transient oligomerization—when multiple protein copies cluster—they momentarily assume semi-organized states that can be selectively recognized and modulated by small molecules.

The study, published in Science Advances, provides a detailed biophysical characterization of these fleeting conformations. Using sophisticated analytical tools, including nuclear magnetic resonance (NMR) spectroscopy and cellular assays, the team shows that a specific small molecule can intercalate into these temporarily rigidified condensates formed by IDP oligomers. This interaction induces an increase in the material rigidity of the condensates, effectively impeding the dysfunctional activity normally propagated by the protein assemblies.

Dr. Salvatella elucidates that the dynamic nature of IDPs should no longer be viewed as an insurmountable barrier. Instead, their propensity to form transiently ordered oligomeric states opens previously unrecognized therapeutic windows. These “moments of vulnerability” arise during protein assembly, creating binding pockets that a drug can exploit, thereby enabling targeted molecular intervention where none existed before.

The complexity of IDPs lies in their plasticity; their structure fluctuates rapidly, complicating the identification of stable druggable sites. However, this research reveals that as individual IDP molecules congregate, collective interactions stabilize certain structural motifs. Such transient, intermediate oligomeric states manifest emergent properties distinct from their monomeric counterparts, including novel binding surfaces critical for therapeutic targeting.

A pivotal advancement made by Dr. Stasė Bielskutė-García and colleagues involves elucidating the molecular mechanism underpinning this modulation. Their findings suggest that by increasing the condensates’ rigidity, the small molecule effectively ‘locks’ IDPs into non-functional states, halting pathological pathways dependent on their dynamic assembly. This mechanistic insight not only clarifies why this compound functions as it does but also informs the rational design of future drugs tailored to bind transient states in intrinsically disordered regions.

Scarce therapeutic options currently exist for diseases heavily driven by disordered proteins, notably aggressive cancers such as small-cell lung cancer and gastrointestinal malignancies. This innovative strategy ushers in a new dimension in drug discovery—one that capitalizes on the dynamic biophysical landscape of IDPs rather than being hindered by it. The ability to pharmacologically manipulate such proteins addresses a critical unmet medical need.

Capitalizing on these insights, IRB Barcelona has spun off Nuage Therapeutics, a pioneering biotechnology company dedicated to developing therapeutics that exploit the transient structural windows of IDPs. Nuage Therapeutics applies a highly specialized drug discovery platform designed to identify and optimize molecular candidates capable of selectively binding these fleeting conformations, setting the stage for breakthrough therapies across oncology and beyond.

Looking forward, Nuage Therapeutics envisions broadening its therapeutic portfolio by deploying this paradigm to diverse diseases characterized by protein disorder. By expanding the toolbox for targeting protein disorder, the company aims to become a leader in this novel field, potentially revolutionizing treatment strategies where conventional approaches have failed.

The study is a testament to the power of fundamental scientific research to catalyze transformative medical innovations. The collaboration between IRB Barcelona, the Max Planck Institute for Molecular Genetics, and the University of Florence underscores the interdisciplinary efforts required to decode the complex behavior of IDPs and harness them for therapeutic gains.

This work was supported by an array of prestigious funding bodies, including the Spanish Ministry of Science, Innovation and Universities, the Agency for Management of University and Research Grants (AGAUR), “la Caixa” Foundation, the Spanish Association Against Cancer (AECC), the Mark Foundation for Cancer Research, and the European Research Council (ERC). Their support affirms the critical importance of investing in cutting-edge basic research with the potential for high-impact clinical translation.

By unlocking the ability to drug intrinsically disordered proteins through their oligomerization-dependent transient states, this study not only pioneers a new frontier in molecular pharmacology but also offers hope for patients with conditions that have challenged traditional drug discovery efforts. The findings herald a new era in which the once “undruggable” may become druggable, fundamentally transforming biomedical science and therapeutic options.

Subject of Research: Intrinsically Disordered Proteins and Their Targeting by Small Molecule Drugs
Article Title: The key to attacking “undruggable” proteins: IRB Barcelona reveals a breakthrough drug mechanism
News Publication Date: March 3, 2026
Web References: https://dx.doi.org/10.1126/sciadv.adz74
References: Science Advances, DOI 10.1126/sciadv.adz74
Image Credits: IRB Barcelona
Keywords: Cancer, Cancer treatments, Proteins, Disordered regions, Target proteins, Intrinsically Disordered Proteins, Oligomerization, Drug discovery, Molecular pharmacology, Small-cell lung cancer, Gastrointestinal cancers